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ABSTRACT: A brief review of Mimosa Pudica (Linn) covering its medicinal value, clinical use 
and Ayurvedic aspects, is presented here. 
 
INTRODUCTION 
 
Mimosa pudica (Linn) Touch –  me  –  not, 
called Lajavanti / Lajjalu must have 
attracted the attention of man, since 
prehistoric times.  Its property to respond to 
touch must have intrigued man and magical 
and  medicinal value must have been 
ascribed to the plant.  The medicinal use of 
the plant dates  back to Caraka (1) and 
Susruta (2).  Mimosa pudica is one of the 
ingredients in a prescription for excessive 
uterine bleeding in a Gujarati Ayurvedic 
book (3).  One of the authors (GHV) was 
impressed by its beneficial effects, when it 
was prescribed by late Yogi Sri 
Ranchhoddasji Maharaj. 
 
Botany: 
 
Mimosa pudica (Linn.) is a commonly found 
weed, growing wildly all over the warm and 
humid zones of India, Africa and tropical 
America.  It belongs to N. O. Leguminosae.  
It is a diffuse, widely spreading shrub 
(Finger 1); 45 to 90 cms in height.  The stem 
and branches are covered with long weak 
bristles and tiny thorns.  The sensitive leaves 
are digitately compound and the leaflets are 
in 12 – 20 pairs, narrow oblong and acute.  
The flowers are small mauvish – pink round 
heads, with a minute calyx.  The pods, 
which are 2.5 to 3.5 cms in length, have fine 
bristles and consist of 3 to 5 one seeded 
joints.  The roots are reddish brown in 
colour, cylindrical, slightly tapering and 
branching in all directions (4). 
 
Pharmacognosy: 
 
Roots of Mimosa pudica have characteristic 
6 to 8 layers of cork cells.  The latter are 
mostly uniform in shape – tangentically cut 
–  rectangular and radially cut –  flattened.  
Under the periderm, thin walled parenchyma 
filled with starch granules constitutes  the 
secondary cortex.  Tannin and rhomboid 
crystals of calcium oxalate are seen in many 
cortical cells.  The cortex is thick.  The 
xylem contains large number of vessels of 
different sizes.  The root powder, greyish 
brown in colour, -  is characterized by – 
starch grains, crystals, cork cells, tannin – 
containing cells, reticulate vessels, pitted 
parenchyma, pitted and nonpitted fibres, thin 
cortical cells, tracheids etc. (5). Pages 156 - 160 
 
 
Phytochemistry (6) 
 
The plant contains an alkaloid – Mimosine 
(CB H 10 04 N2) – in very small quantities.  
It is identical with leucinal.  The essential oil 
contains furnisal, linalool, geraniol and 
several aldehydes including anise aldehyde 
and benzaldehyde.  An adrenaline –  like 
substance has been identified in the extract 
of leaves of Mimosa pudica.  Crocetin 
dimethylester has been detected in the 
pulvini of the plant.  The flowers show the 
presence of proteins, carbohydrates, fats, 
fibres and ash.  Leaves and stem do no 
contain quinine or quinidine.  Flavonids, 
acting on capillaries and small blood 
vessels, have to be investigated in the plant.  
The roots contain 10% tannin, ash, calcium 
oxalate crystals and mimosine. 
 
Medicinal Uses:  
 
Desai ascribes haemostatic use of the plant 
to its action on small blood vessels (7).  The 
root is used for dysentary with blood / 
mucus, piles and urinary calculi. The fresh 
juice of leaves is given internally to stop 
bleeding.  The paste of the leaves is applied 
externally on piles, fissures, skin wounds, 
ulcers, etc.  In southern India, the plant is 
used for piles.  In South –  East Asia viz 
Cambodia, Mimosa pudica has a reputation 
for therapeutic effect on vesical calculi (8).  
The root powder was prescribed in a dose of 
2 – 3 gms. Along with curds, as mentioned 
by M. S. Vaidya (9).  The root powder, in a 
paste form is also applied to vaginal 
prolapse. 
 
Plant Material and Medication 
 
Mimosa pudica (Linn.), identified properly 
by botany and pharmacognosy, was 
commercially purchased from known 
pharmaceutical and herb – merchants.  The 
roots were cleansed, washed, dried in shade 
and pulverized.  The root powder was 
extracted with water.  This dry aqueous 
extract was used for the acute toxicity 
studies in mice and observational studies in 
rats.  For the medication in patients the 
formulations of Mimosa pudica were 
utilized.  The standardized extract was 
prepared at Haffkine Institute.  The dose of 
the dry extract was 5 – 10 ml three to four 
times in a  day.  Subsequently, the 
micronized powder of the dry extract was 
used in capsules of 500mg. 2 – 3 capsules t. 
d. s. in 2 patients.  The equivalence of the 
dose was maintained on the basis of the 
water evaporation.  One patient opted for 
fresh paste of the root, prepared at home. 
 
Acute Toxicity 
 
The aqueous dry extract of Mimosa pudica 
was injected intraperitoneally in rats as a 
suspension of carboxymethyl cellulose (80 
mg/ml).  Groups of five rats each were given 
200, 400, 600 and 1600 mg/kg of the 
suspension of Mimosa pudica.   Only mild 
sedation was observed for 1 hour.  No 
deaths occurred. 
 
In albino female mice, the root extract of 
Mimosa pudica  was given intraperitoneally 
in doses of 100, 200, 400 and 800 mg / kg.  
Table 1 shows the results.  The LD 100 was 
400 mg/kg and    LD o was 100 mg/kg. 
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TABLE – 1 
 
Acute Toxicity in Mice 
 
 
Dose mg / kg 
 
 
Mortality at 24 hours 
100 
 
200 
 
400 
 
800 
 
0/5 
 
3/5 
 
5/5 
 
5/5 
 
 
Pilot clinical use  
 
Nine women – 2 unmarried and 7 married – 
who presented with heavy menstrual blood 
loss were studied.  The woman ranged in 
age from 14 to 40 years.  Their verbal 
consent was obtained for this pilot 
therapeutic study.  As it is difficult to design 
a controlled clinical trial in the condition 
like excessive menstrual bleeding, it was 
decided to conduct pilot studies of an 
exploratory nature to assess for tolerability 
of the plant and beneficial activity, if any. 
 
Patient 1 NB 
 
This unmarried  woman of 20 years age, 
since menarche had complained of 
premenstrual tension, dysmenorrhoea and 
vomiting that was followed by menorrhagia.  
The cycle length was 30 days and the period 
usually lasted with partial relief, for 5 days.  
In past she had tried inj. Progestin, 
Asokarista and antispasmodics.  She was 
treated for 3 cycles;  the dose of distilled 
extract was       5 ml x 3 during the period 
and 5 ml x 2 between the periods.  The 
excessive menstrual flow was relieved 
during all the three cycles.  However, nausea 
vomiting and dysmenorrhoea were 
dramatically relieved when Asokarista was 
added.  When the drugs were discontinued 
all the symptoms recurred during the next 
cycles.  There were no side effects. 
 
Patient 2 NB 
 
Unmarried girl,  aged 14 years, presented 
with moderate continuous menstrual 
bleeding for last one month.  She was 
prescribed the distilled extract 5ml x 3 to 4, 
during bleeding and twice in a day later, for 
a period of 3 months.  The excessive 
bleeding decreased in the next cycle and was 
normal during the follow up period.  There 
were no side effects of the drug.  The patient 
had menarche two years before presentation, 
followed by a period of amenorrhoea until 
the heavy period. 
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Patient 3 KH 
 
Woman, aged 35 years with a history of 2 
full – term normal deliveries presented with 
profuse menstrual bleeding.  She usually had 
occasional episodes of such profuse 
bleeding, with regular cycles.  Vaginal 
examination was normal.  She was 
prescribed a dose of 15 ml of the extract 
every hour, until the bleeding was 
controlled.  The bleeding was relieved after 
two doses and she could go out by the 
evening.  She did not report for follow up 
until 4 years when the profuse bleeding 
recurred.  She had no complaints in the 
interim period. 
 
Patient 4 DL 
 
Woman, aged 40 years  with 9 full – term 
normal deliveries presented with profuse 
menstrual bleeding for last two years.  On 
Pelvic examination, uterus and adenexa 
were normal.  She was prescribed 
micronized powder in capsules – 1000 mg 
twice in a day for two months.  Her 
excessive bleeding responded in the first 
cycle and was relieved  more than 50% 
during the second cycle.  Previously, she 
was passing clots and having 3 – 4 sari – pad 
changes and had to lie down in bed.  All this 
changed and she continued on a dose of 500 
mg.  B.D. to have relief.  There were no 
adverse effects observed. 
 
Patient 5 VA 
 
Woman, aged 35 years, with a full – term 
normal delivery had severe menorrhagia for 
last ten years.  She had 28 day cycle with 4 
day menstruation.  Pelvic and general 
examination was normal.  She was 
prescribed the paste of fresh roots 5ml with 
honey and black pepper every 2 hours, 
during the menstrual period.  The excessive 
bleeding responded well.  She continued to 
take the extract for first three days of the 
period, for 2 years, with good control.  In 
spite of use for 2 years, no side effects were 
observed. 
 
Patient 6 MK 
 
Woman, aged 34 years,  with 2 full term 
normal deliveries and one miscarriage, 
presented with sever menorrhagia.  The 
cycle length was of 28 days and the bleeding 
lasted for 5 to 6 days.  The pelvic and 
general examinations were normal.  With 
the extract and later with the capsules, the 
patient was relieved of her excessive 
menstrual blood loss.  The patient was 
treated for 4 years, with good control.  The 
long term therapy did not show any side 
effects of Mimosa pudica.  The patient had a 
pregnancy and full – term normal delivery at 
the end of 4 years. 
 
Patient 7 PB 
 
Woman, aged 35 years, had a history of a 
miscarriage.  She presented with severe 
menorrhagia with cycle length of 20 to 25 
days, with menstruation for 4 to 5 days.  She 
was treated with capsules 100 mg B.D. 
during the period and 500 mg. B.D. as a 
maintenance dose.  The pelvic and general 
examinations were normal.  She responded 
well and excessive bleeding stopped.  She 
was observed for 2 cycles and left for her 
native place.  
 
Patient 8 TH 
 
Woman, aged 30 years, had 2 full –  term 
normal deliveries.  She presented with 
menorrhagia of 4 years duration.  She had 
been treated by several gynaecologists for 
dysfunctional uterine bleeding.  Even blood 
transfusion had to be given.  The hormonal 
treatment was discontinued prior to the 
administration of Mimosa pudica.  With Pages 156 - 160 
 
Mimosa pudica  capsules 500 mg x 3 the 
prolonged excessive bleeding responded 
dramatically within 2 days.  The patient 
missed the period while Mimosa pudica was 
being continued in a dose of 500 mg x 2.  
She delivered a healthy baby at full term, 
with no defects. 
 
Patient 9 SR 
 
Woman, aged 35 years,  had 8 full –  term 
normal deliveries.  She complained of 
menorrhagia after dilatation and curettage 
for incomplete abortion.  The patient was 
pale and had cycle length of 25 days with 3 
to 4 days duration of flow.  Extract of 
Mimosa pudica was given initially 15 ml. 2 
hourly.   She was treated with standard dose 
for 4 months and her cycles continued to be 
normal,  and the excessive bleeding was 
controlled.  There were no side effects. 
 
 
Comments 
 
The plant Mimosa pudica (Linn.) in these 
pilot studies, has shown promise in further 
detailed trials in a larger sample size of 
patients with dysfunctional uterine bleeding.  
The tolerability of Mimosa pudica was good 
and still it is desirable to carry out 
conventional phase 1 studies with organ 
function tests, prior to embarking on a large 
scale phase III studies.   There is an urgent 
need to conduct a survey of traditional 
plants useful in menorrhagia, 
dysmenorrhoea and related disorders.  Such 
a survey may identify plants with potential 
therapeutic value.  A team approach for 
involving such a study is desirable; vaidyas 
clinical pharmacologists, gynaecological 
endocrinologists, botanists and medicinal 
chemists, should pool their expertise for a 
meaningful research project. 
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